StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$690.24−10.41 (-1.49%)

Close on Nov 17, 2026Market cap $54.38BP/E 48.5Yield –

IDEXX Laboratories ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

IDEXX Laboratories's ebitda for the twelve months ending Jun 30, 2026 was $1.61B, up 15.8% year over year. For fiscal 2025 it was $1.51B, up 19.6% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $1.51B in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.51B+19.6%
FY2024Dec 31, 2024$1.26B+3.8%
FY2023Dec 31, 2023$1.21B+19.9%
FY2022Dec 31, 2022$1.01B-2.5%
FY2021Dec 31, 2021$1.04B+31.1%
FY2020Dec 31, 2020$790.52M+23.4%
FY2019Dec 31, 2019$640.86M+11.5%
FY2018Dec 31, 2018$574.51M+15.8%
FY2017Dec 31, 2017$496.17M+15.8%
FY2016Dec 31, 2016$428.46M+16.2%
FY2015Dec 31, 2015$368.87M+15.6%
FY2014Dec 31, 2014$319.14M-0.7%
FY2013Dec 31, 2013$321.36M+2.0%
FY2012Dec 31, 2012$314.97M+10.7%
FY2011Dec 31, 2011$284.43M+13.8%
FY2010Dec 31, 2010$249.84M+10.7%
FY2009Dec 31, 2009$225.74M+2.4%
FY2008Dec 31, 2008$220.44M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$466.62M+14.1%
Q1 FY2026Mar 31, 2026$400.27M+14.2%
Q4 FY2025Dec 31, 2025$354.33M+20.0%
Q3 FY2025Sep 30, 2025$391.47M+15.8%
Q2 FY2025Jun 30, 2025$408.82M+38.1%
Q1 FY2025Mar 31, 2025$350.60M+6.6%
Q4 FY2024Dec 31, 2024$295.39M+7.4%
Q3 FY2024Sep 30, 2024$338.03M+11.1%
Q2 FY2024Jun 30, 2024$295.99M-8.6%
Q1 FY2024Mar 31, 2024$328.86M+6.5%
Q4 FY2023Dec 31, 2023$275.04M+7.8%
Q3 FY2023Sep 30, 2023$304.27M+11.3%
Q2 FY2023Jun 30, 2023$324.00M+56.4%
Q1 FY2023Mar 31, 2023$308.73M+12.3%
Q4 FY2022Dec 31, 2022$255.25M+12.5%
Q3 FY2022Sep 30, 2022$273.38M+8.3%
Q2 FY2022Jun 30, 2022$207.19M-27.2%
Q1 FY2022Mar 31, 2022$274.86M+0.8%
Q4 FY2021Dec 31, 2021$226.89M+8.2%
Q3 FY2021Sep 30, 2021$252.43M+28.5%
Q2 FY2021Jun 30, 2021$284.63M+31.3%
Q1 FY2021Mar 31, 2021$272.68M+62.8%
Q4 FY2020Dec 31, 2020$209.66M+51.7%
Q3 FY2020Sep 30, 2020$196.51M+21.1%
Q2 FY2020Jun 30, 2020$216.83M+16.6%
Q1 FY2020Mar 31, 2020$167.53M+8.4%
Q4 FY2019Dec 31, 2019$138.22M+1.7%
Q3 FY2019Sep 30, 2019$162.25M+17.4%
Q2 FY2019Jun 30, 2019$185.90M+11.7%
Q1 FY2019Mar 31, 2019$154.49M+15.4%
Q4 FY2018Dec 31, 2018$135.95M+13.9%
Q3 FY2018Sep 30, 2018$138.23M+14.1%
Q2 FY2018Jun 30, 2018$166.49M+16.3%
Q1 FY2018Mar 31, 2018$133.85M+18.9%
Q4 FY2017Dec 31, 2017$119.33M+14.7%
Q3 FY2017Sep 30, 2017$121.14M+11.9%
Q2 FY2017Jun 30, 2017$143.15M–
Q1 FY2017Mar 31, 2017$112.55M–
Q4 FY2016Dec 31, 2016$104.07M–
Q3 FY2016Sep 30, 2016$108.23M–

More IDEXX Laboratories figures

See a number that looks wrong?